SCHEMBL6483460

SCHEMBL6483460

O=C(O)/C=C1/NCCc2cc(OC(F)(F)F)ccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGM2 P21980 1/20 0.42
GPR3 P46089 5/20 0.40
KMT2A Q03164 5/20 0.39
MEN1 O00255 3/20 0.39
CES1 P23141 1/20 0.38
ALDH1A1 P00352 1/20 0.38
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
THRB P10828 1/20 0.38
TRPV1 Q8NER1 1/20 0.37
PIM1 P11309 1/20 0.36
PPARD Q03181 1/20 0.35
PPARA Q07869 1/20 0.35
NPC1 O15118 1/20 0.35
TSHR P16473 1/20 0.35
PDK1 Q15118 1/20 0.35
PDK2 Q15119 1/20 0.35
PDK3 Q15120 1/20 0.35
PDK4 Q16654 1/20 0.35
OPRM1 P35372 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6483465 1.00 TGM2 (0.42) TGM2GPR3KMT2AMEN1CES1
SCHEMBL6483454 1.00 TGM2 (0.42) TGM2GPR3KMT2AMEN1CES1
SCHEMBL6485760 0.83 KMT2A (0.54) KMT2AMEN1ALDH1A1GAANPC1
SCHEMBL3865950 0.83 KMT2A (0.54) KMT2AMEN1ALDH1A1GAANPC1
SCHEMBL3865953 0.83 KMT2A (0.54) KMT2AMEN1ALDH1A1GAANPC1
SCHEMBL16346860 0.78 PARP10 (0.54) CES1
SCHEMBL7048394 0.72 KMT2A (0.54) KMT2AMEN1ALDH1A1NPC1
SCHEMBL7048398 0.72 KMT2A (0.54) KMT2AMEN1ALDH1A1NPC1
SCHEMBL7048396 0.72 KMT2A (0.54) KMT2AMEN1ALDH1A1NPC1
SCHEMBL6485271 0.71 PDPK1 (0.53) KMT2AMEN1CES1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6930114-B2 Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors BAYER PHARMACEUTICALS CORPORATION (US) 2005-08-16 US disclosed
US-20040138249-A1 Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors BAYER PHARMACEUTICALS CORPORATION 2004-07-15 US disclosed
EP-1347973-A1 PYRROLO (2.1-A) DIHYDROISOQUINOLINES AND THEIR USE AS PHOSPHODIESTERASE 10A INHIBITORS Bayer Aktiengesellschaft (DE) 2003-10-01 EP disclosed
WO-2002048144-A1 PYRROLO (2.1-A) DIHYDROISOQUINOLINES AND THEIR USE AS PHOSPHODIESTERASE 10A INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2002-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138249-A1 Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors PDE7B, PDE2A, PDE5A TGM2 3018/4885GPR3 2931/4885KMT2A 1344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.